A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
An article from
Dive Brief
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
Published April 27, 2026
Oruka Therapeutics is developing a drug for plaque psoriasis.
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to…
Adding tirzepatide helped patients shed pounds, improved complete skin clearance rates
Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according…
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost…
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs…
